HAVCR1 and prostate cancer: This current study initially examined serum HAVcR-1 ectodomain levels in prostate cancer, which showed decreased serum HAVcR-1 ectodomain levels in comparison to healthy control levels, and a significance decrease in serum HAVcR-1 ectodomain levels in the Gleason score of 6, 7, 8, 9 and 10 prostate cancers, in comparison to healthy control levels.